Humana (HUM) Stock
US health insurer with Medicare Advantage and care services. Here's the price, business snapshot, and what's worth knowing about Humana in October 2026.
Humana Inc (HUM) is a major US health insurance and services company, best known for its large Medicare Advantage business alongside commercial and Medicaid plans. With a market cap around $35.5bn, Humana generates revenues from premiums, care-management services and health-services initiatives that aim to lower costs and improve outcomes. Investors often watch Humana for its exposure to the growing Medicare Advantage market and its push into value-based care, primary-care partnerships and home health services, which can offer structural growth if executed well. Key considerations include reimbursement policy, regulatory oversight, medical-cost trends and membership retention. The stock can be sensitive to election-driven healthcare policy and short-term claims volatility. This summary is educational and not personalised investment advice; returns are not guaranteed and the value of investments can fall as well as rise. Consider your goals, risk tolerance and seek independent advice before investing.
Why It’s Moving
Humana Shares Surge on Barclays Upgrade Amid Insider Litigation Concerns
- Barclays upgraded Humana from neutral, setting a new $515 price target which triggered a 7% jump in share value.
- A separate report alleges potential breaches of fiduciary duties by Humana insiders, prompting shareholder outreach for legal options.
- While Humana rallied, peer UnitedHealth saw only modest gains, highlighting the specific impact of the analyst action on this ticker.
Humana Shares Surge on Barclays Upgrade Amid Insider Litigation Concerns
- Barclays upgraded Humana from neutral, setting a new $515 price target which triggered a 7% jump in share value.
- A separate report alleges potential breaches of fiduciary duties by Humana insiders, prompting shareholder outreach for legal options.
- While Humana rallied, peer UnitedHealth saw only modest gains, highlighting the specific impact of the analyst action on this ticker.
Sixth Month Growth Performance
When is the next earnings date for Humana (HUM)?
Humana has not yet announced a confirmed date for its next earnings report. Based on the company's historical reporting pattern, which typically occurs approximately three months after the previous release, the next report is expected in late October 2026. This upcoming disclosure will cover financial results for the third quarter of fiscal year 2026.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Humana's stock, as its value may rise above the current price.
Financial Health
Humana is producing strong revenue and cash flow, indicating solid financial performance and stability.
Dividend
Humana's low dividend yield of 0.91% indicates limited returns for dividend-seeking investors. If you invested $1000 you would be paid $9.10 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Medicare Advantage Focus
Humana’s scale in Medicare Advantage can be a structural growth engine, though outcomes depend on policy and medical-cost trends.
Care-Delivery Push
Investors may watch its moves into value-based care and home health since these can improve margins over time, but execution risk remains.
Regulatory Sensitivity
Policy and reimbursement changes materially affect profits and membership; consider regulatory risk alongside growth opportunities.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
